Inventiva
ISIN: FR0013233012 | Ticker: IVA | LEI: 969500I9Y690B3FZW590
Country: France
We are a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.
We have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. By leveraging these assets and expertise, we are advancing two clinical candidates in two indications, as well as a deep pipeline of earlier stage programs.
2011
Served areaWorldwide
Headcount105
Headquarters50 Rue de Dijon, 21121 Daix – France
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Assets | N/A | 56,960,000.00 | 138,920,000.00 | 121,985,000.00 | 116,004,000.00 |
| Noncurrent Assets | N/A | 8,084,000.00 | 5,923,000.00 | 6,408,000.00 | 9,621,000.00 |
| Property Plant And Equipment | N/A | 3,721,000.00 | 3,282,000.00 | 3,196,000.00 | 7,385,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 1,228,000.00 | 935,000.00 | 770,000.00 | 568,000.00 |
| Other Noncurrent Assets | N/A | 3,135,000.00 | 1,706,000.00 | 2,442,000.00 | 1,668,000.00 |
| Current Assets | N/A | 48,875,000.00 | 132,997,000.00 | 115,578,000.00 | 106,383,000.00 |
| Inventories | N/A | 387,000.00 | 320,000.00 | 392,000.00 | 373,000.00 |
| Current Trade Receivables | N/A | 4,000.00 | 48,000.00 | 4,000,000.00 | 0.00 |
| Cash and cash equivalents | 56,692,000.00 | 35,840,000.00 | 105,687,000.00 | 86,553,000.00 | 86,736,000.00 |
| Other Current Assets | N/A | 2,811,000.00 | 17,914,000.00 | 20,260,000.00 | 13,267,000.00 |
| Equity And Liabilities | N/A | 56,960,000.00 | 138,920,000.00 | 121,985,000.00 | 116,004,000.00 |
| Equity | 61,596,000.00 | 41,392,000.00 | 111,211,000.00 | 88,866,000.00 | 45,476,000.00 |
| Issued Capital | N/A | 268,000.00 | 386,000.00 | 409,000.00 | 421,000.00 |
| Retained Earnings Profit Loss For Reporting Period | N/A | N/A | -33,619,000.00 | -49,635,000.00 | -54,274,000.00 |
| Share Premium | N/A | 86,012,000.00 | 139,668,000.00 | 165,072,000.00 | 173,886,000.00 |
| Noncurrent Liabilities | N/A | 1,703,000.00 | 13,800,000.00 | 10,266,000.00 | 39,827,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 1,127,000.00 | 1,385,000.00 | 1,429,000.00 | 1,234,000.00 |
| Other Longterm Provisions | N/A | 574,000.00 | 2,377,000.00 | 0.00 | 0.00 |
| Noncurrent Contract Liabilities | N/A | N/A | 0.00 | 0.00 | 55,000.00 |
| Noncurrent Derivative Financial Liabilities | N/A | N/A | 0.00 | 0.00 | 9,876,000.00 |
| Longterm Borrowings | N/A | 2,000.00 | 10,037,000.00 | 8,837,000.00 | 28,663,000.00 |
| Current Liabilities | N/A | 13,865,000.00 | 13,908,000.00 | 22,853,000.00 | 30,701,000.00 |
| Current Provisions | N/A | 1,264,000.00 | 130,000.00 | 180,000.00 | 0.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 7,491,000.00 | 6,923,000.00 | 14,602,000.00 | 19,359,000.00 |
| Current Contract Liabilities | N/A | N/A | 0.00 | 0.00 | 6,000.00 |
| Other Current Liabilities | N/A | 4,998,000.00 | 6,838,000.00 | 6,789,000.00 | 5,485,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 113,000.00 | 18,000.00 | 1,282,000.00 | 5,851,000.00 |
| Line item in (eur) | 01.01.2019/ 01.01.2020 |
01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|---|
| Revenue | 6,998,000.00 | 372,000.00 | 4,194,000.00 | 12,179,000.00 |
| Profit Loss From Operating Activities | -30,312,000.00 | -29,718,000.00 | -52,114,000.00 | -57,110,000.00 |
| Finance Income | 175,000.00 | 2,057,000.00 | 5,478,000.00 | 4,923,000.00 |
| Finance Costs | 81,000.00 | 5,959,000.00 | 2,635,000.00 | 2,107,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 364,000.00 | -20,000.00 |
| Profit (loss) | -30,218,000.00 | -33,619,000.00 | -49,635,000.00 | -54,274,000.00 |
| Line item in (eur) | 01.01.2019 | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|---|
| Profit (loss) | N/A | -30,218,000.00 | -33,619,000.00 | -49,635,000.00 | -54,274,000.00 |
| Adjustments For Income Tax Expense | N/A | 0.00 | 0.00 | 32,000.00 | -84,000.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 22,000.00 | 68,000.00 | -72,000.00 | 19,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 0.00 | 3,039,000.00 | -5,198,000.00 | 343,000.00 |
| Adjustments For Sharebased Payments | N/A | 1,407,000.00 | 938,000.00 | 2,089,000.00 | 2,218,000.00 |
| Adjustments For Fair Value Gains Losses | N/A | 0.00 | -1,791,000.00 | 651,000.00 | 407,000.00 |
| Other Adjustments For Noncash Items | N/A | 0.00 | 41,000.00 | 0.00 | 0.00 |
| Other Inflows Outflows Of Cash Classified As Operating Activities | N/A | 403,000.00 | -2,853,000.00 | -1,231,000.00 | -1,685,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -28,404,000.00 | -30,590,000.00 | -47,629,000.00 | -44,928,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | N/A | -693,000.00 | -571,000.00 | -47,000.00 | -1,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -826,000.00 | -8,557,000.00 | -1,793,000.00 | 8,868,000.00 |
| Proceeds From Issuing Shares | N/A | 8,654,000.00 | 101,782,000.00 | 25,475,000.00 | 8,827,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 0.00 | 9,979,000.00 | 0.00 | 30,209,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 146,000.00 | 61,000.00 | 13,000.00 | 1,033,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 130,000.00 | 26,000.00 | 15,000.00 | 735,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 8,378,000.00 | 111,674,000.00 | 25,447,000.00 | 37,268,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | -20,852,000.00 | 72,527,000.00 | -23,975,000.00 | 1,208,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | 0.00 | -2,681,000.00 | 4,841,000.00 | -1,025,000.00 |
| Cash and cash equivalents | 56,692,000.00 | 35,840,000.00 | 105,687,000.00 | 86,553,000.00 | 86,736,000.00 |
Please note that some sums might not add up.
FR0013233012
LEI969500I9Y690B3FZW590
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.